Fig. 3From: Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysisExacerbation rates when treated with biologics acting on the interleukin 5 pathway [15, 36,37,38,39,40,41,42]. Median Annualized Exacerbation rate (95% CI). Forest plot of the exacerbation rates among the placebo and IL-5 agent armsBack to article page